Status:
COMPLETED
Sildenafil For Meniere's Disease
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Meniere's Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Meniere's disease affects a person's sense of balance. An attack can last 20 minutes to 2 hours or longer. Symptoms include rotational vertigo, hearing loss, tinnitus and a sensation of fullness in th...
Eligibility Criteria
Inclusion
- Active Meniere's disease (2 or more definitive spontaneous episodes of vertigo 20 minutes or longer, plus hearing loss on at least 1 occasion, tinnitus or aural fullness) with confirmed diagnosis
Exclusion
- Pregnant or breast feeding females or fertile females unwilling to use agreed contraceptive methods
- severe Meniere's diseased (more than 8 attacks per month)
- previous ear surgery
- intratympanic perfusions of steroids or gentamicin; requiring other medications contraindicated for Viagra (eg. nitrates)
- with medical conditions that make Viagra contraindicated
Key Trial Info
Start Date :
June 18 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 8 2006
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00145483
Start Date
June 18 2002
End Date
November 8 2006
Last Update
February 1 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bondi Junction, New South Wales, Australia
2
Pfizer Investigational Site
Brisbane, Queensland, Australia
3
Pfizer Investigational Site
East Melbourne, Victoria, Australia
4
Pfizer Investigational Site
Melbourne, Victoria, Australia